Skip to Content

Tag: Insulet


News

In brief: Nationwide Medical ‘unlocks potential,’ Dynamic Infusion makes buy, Insulet awarded damages 

December 13, 2024HME News Staff

CALABASAS, Calif. – Nationwide Medical, a sleep and respiratory provider that operates in 49 states and serves more than 100,000 patients, has formed a growth partnership with Heritage Group, a health care-focused private equity firm.   “Today marks an exciting milestone for Nationwide Medical,” said CEO David Siegel. “We have operated as a family-owned business for over 20 years and are incredibly proud of our continued dedication to putting patients first and...

Dynamic Infusion, Insulet, Nationwide Medical, Private Equity


Read Full Articlered right arrow icon

Also Noted

Insulet’s Omnipod integrates with Libre

November 21, 2024HME News Staff

ACTON, Mass. – Insulet’s Omnipod 5 Automated Insulin Delivery System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring sensor in the U.S. “We are excited to announce that Omnipod 5, the only AID system indicated for both Type 1 and Type 2 diabetes, is now integrated with Abbott’s FreeStyle Libre 2 Plus sensor in the U.S.,” aid Eric Benjamin, Insulet’s executive vice president and chief product and customer experience officer....

Continuous Glucose Monitor (CGM), Diabetes, Insulet, Libre, Omnipod


Read Full Articlered right arrow icon

Also Noted

Insulet sees ‘robust’ Q3

November 8, 2024HME News Staff

ACTON, Mass. – Insulet reported revenue of $543.9 million for the third quarter of 2023, an increase of 25.7%. Total Omnipod revenue was $533.6 million, an increase of 26.4%; of that, U.S. Omnipod revenue was $395.6 million and international Omnipod revenue was $138 million. “We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, president and CEO. “Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both...

Diabetes, Insulet, Omnipod


Read Full Articlered right arrow icon

Also Noted

Insulet to mark National Diabetes Awareness month

November 6, 2024HME News Staff

ACTON, Mass. – Insulet will recognize National Diabetes Awareness Month and World Diabetes Day with a series of activities in November. The company will sponsor the American Diabetes Association’s two-day community event Nov. 22 – 23 in Boston and will exhibit at the ADA Community Day of Access, which includes free health care screenings and more. “People with diabetes must make dozens of decisions every day to manage their condition, which can be incredibly stressful, overwhelming...

Diabetes, Insulet, National Diabetes Awareness Month


Read Full Articlered right arrow icon

Also Noted

Omnipod 5 cleared for Type 2 diabetes management

August 28, 2024HME News Staff

ACTON, Mass. – Insulet has received clearance from the U.S. Food and Drug Administration for its Omnipod 5 Automated Insulin Delivery System for people with Type 2 diabetes, making it the only such device cleared by the FDA for both Type 1 and Type 2 diabetes management. “Today’s announcement represents a significant milestone in providing easy-to-use, patient-centric technology for the treatment of Type 2 diabetes,” said Jim Hollingshead, Insulet president and CEO. “Insulet...

Diabetes Supplies, Insulet, Omnipod 5


Read Full Articlered right arrow icon

News

In brief: OPGA names finalists, Insulet grows, Breas corrects 

August 14, 2024HME News Staff

WATERLOO, Iowa – The Orthotic and Prosthetic Group of America has announced the four finalists nominated for the 2024 O&P Woman of the Year Award.  The finalists are:  Dr. Justina Appel, PhD, CO, BOCP, LPO, clinical specialist with NuTech Synergies;  Jenna Calomeris, vice president of sales with ThorWear, DBA Elevate Movement;  Dr. Sara Peterson, PhD, L/CPO, FAAOP(D), clinical research scientist/certified prosthetist orthotist (CPO) with O&P Clinical Innovations;...

Breas Medical, Insulet, Orthotic & Prosthetic Group of America (OPGA)


Read Full Articlered right arrow icon

Specialty Providers

Insulet: ‘2024 is shaping up to be another year of rapid growth’ 

August 13, 2024HME News Staff

ACTON, Mass. – Insulet has reported revenue of $488.5 million for the second quarter of 2024, a 23.2% increase year over year, exceeding the high end of the company’s guidance, driven by outperformance for all product lines.  Total Omnipod revenue was $480.4 million, a 26.3% increase, including $352.3 million in the U.S., a 27.3% increase.  “2024 is shaping up to be another year of rapid growth, fueled by strong Omnipod 5 demand and our accelerating pace of product...

Diabetes, Insulet, Omnipod


Read Full Articlered right arrow icon

News

In brief: Philips sues SoClean – again, AAH re-engages lawmakers, Enos re-enters sleep market

May 17, 2024HME News Staff

PITTSBURGH – Philips has sued SoClean in a bid to get the company, whose ozone cleaners it says “attacks” the foam in its CPAP devices, to pay part of its recently announced $1.1 billion settlement.  Philips announced the settlement in April to resolve the personal injury litigation and the medical monitoring class action related to a recall of certain sleep and respiratory devices in the U.S.    “(SoClean’s) negligent and intentionally misleading...

Enos Home Medical, Insulet, Philips, SoClean, United Spinal Association


Read Full Articlered right arrow icon

Also Noted

Insulet reports earnings increase, gains market share

May 15, 2024HME News Staff

ACTON, Mass. – Insulet reported revenue of $441.7 million for the first quarter 2024, an increase of 23.3% compared to the prior year. Total Omnipod revenue was $433.0 million, an increase of 21.1%, with U.S. Omnipod revenue $317.7 million. “We are pleased with our strong first quarter results, which underscore the strength of our advanced technology platform and deep competitive advantages,” said Jim Hollingshead, president and CEO. “During the quarter, we achieved strong...

Diabetes, Insulet, Omnipod


Read Full Articlered right arrow icon

Also Noted

Insulet’s Omnipod fuels growth

February 23, 2024HME News Staff

ACTON, Mass. – Insulet reported full year 2023 revenues $1.7 billion, up 30% compared to 2022. Fourth quarter 2023 revenue was $509.8 million, up nearly 38%. Total Omnipod revenue was $501 million; of that, US Omnipod revenue was $394.6 million, an increase of nearly 43%. “2023 was another transformational year for Insulet,” said Jim Hollingshead, president & CEO. “The rapid adoption of Omnipod 5 helped fuel our eighth consecutive year of more than 20% constant currency revenue...

Diabetes, Insulet, Insulin pump, Omnipod


Read Full Articlered right arrow icon